trending Market Intelligence /marketintelligence/en/news-insights/trending/KxHjILbGzDkpmTvF8GmAnw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Federal appeals court backs Sanofi in prostate cancer drug patent case

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Federal appeals court backs Sanofi in prostate cancer drug patent case

The U.S. Court of Appeals for the Federal Circuit affirmed the validity of Sanofi's patent for prostate cancer drug Jevtana.

The federal court's decision also reversed an earlier ruling by the U.S. District Court for the District of New Jersey which invalidated Sanofi's patent on the method of using Jevtana.

Paris-based Sanofi's Sanofi-Aventis U.S. LLC unit sued generic-drug companies Dr. Reddy's Laboratories Ltd., Fresenius Kabi USA LLC, Accord Healthcare Inc., Apotex Inc., Actavis LLC and Mylan NV for patent infringement.

Jevtana is approved by the U.S. Food and Drug Administration to treat men whose prostate cancer is resistant to medical or surgical treatments that lower testosterone and has worsened after prior therapies. The drug generated €126 million in sales during the second quarter of 2019.